Veracyte, Inc. (VCYT) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
VCYT Revenue Growth
Revenue Breakdown (FY 2025)
VCYT's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
VCYT Revenue Analysis (2014–2025)
As of May 8, 2026, Veracyte, Inc. (VCYT) generated trailing twelve-month (TTM) revenue of $541.7 million, reflecting exceptional growth of +21.5% year-over-year. The most recent quarter (Q1 2026) recorded $139.1 million in revenue, down 1.1% sequentially.
Looking at the longer-term picture, VCYT's 5-year compound annual growth rate (CAGR) stands at +34.5%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $517.1 million in 2025, representing a new all-time high.
Revenue diversification analysis shows VCYT's business is primarily driven by Testing (95%), Product (3%), and Biopharmaceutical And Other (2%). With over half of revenue concentrated in Testing, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including EXAS (+17.7% YoY), NTRA (+35.9% YoY), and CDNA (+19.2% YoY), VCYT has underperformed the peer group in terms of revenue growth. Compare VCYT vs EXAS →
VCYT Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| VCYTCurrent | $542M | +21.5% | +34.5% | 14.3% | |
 EXAS | $3.2B | +17.7% | +16.8% | -6.4% | |
 NTRA | $2.3B | +35.9% | +42.6% | -13.4% | |
 CDNA | $380M | +19.2% | +14.6% | -5.5% | |
 ACNB | $170M | - | - | 27.3% | |
 PAHC | $1.3B | +32.4% | +10.1% | 8.5% |
VCYT Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $517.1M | +16.0% | $360.0M | 69.6% | $74.2M | 14.3% |
| 2024 | $445.8M | +23.5% | $298.1M | 66.9% | $16.1M | 3.6% |
| 2023 | $361.1M | +21.8% | $248.1M | 68.7% | $-85,795,000 | -23.8% |
| 2022 | $296.5M | +35.1% | $195.0M | 65.7% | $-41,081,000 | -13.9% |
| 2021 | $219.5M | +86.8% | $145.1M | 66.1% | $-81,903,000 | -37.3% |
| 2020 | $117.5M | -2.4% | $76.0M | 64.7% | $-35,389,000 | -30.1% |
| 2019 | $120.4M | +30.8% | $83.8M | 69.7% | $-15,127,000 | -12.6% |
| 2018 | $92.0M | +27.9% | $58.9M | 64.0% | $-22,233,000 | -24.2% |
| 2017 | $72.0M | +10.6% | $43.8M | 60.8% | $-26,538,000 | -36.9% |
| 2016 | $65.1M | +31.5% | $39.6M | 60.9% | $-28,803,000 | -44.3% |
See VCYT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs VCYT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare VCYT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonVCYT — Frequently Asked Questions
Quick answers to the most common questions about buying VCYT stock.
Is VCYT's revenue growth accelerating or slowing?
VCYT revenue is accelerating at +21.5% year-over-year, exceeding the 5-year CAGR of +34.5%. TTM revenue reached $542M. Growth momentum has increased versus prior periods.
What is VCYT's long-term revenue growth rate?
Veracyte, Inc.'s 5-year revenue CAGR of +34.5% reflects the sustained expansion pattern. Current YoY growth of +21.5% is above this long-term average.
How is VCYT's revenue distributed by segment?
VCYT reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.